Vestronidase Alfa
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12366 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 25 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Scheie syndrome | KG + DL |
| 2 | lysosomal storage disease with skeletal involvement | KG + DL |
| 3 | Hurler syndrome | KG + DL |
| 4 | Sanfilippo syndrome | KG + DL |
| 5 | camptodactyly, myopia, and fibrosis of the medial rectus muscle of eye | KG + DL |
| 6 | ptosis-vocal cord paralysis syndrome | KG + DL |
| 7 | ptosis-strabismus-ectopic pupils syndrome | KG + DL |
| 8 | ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome | KG + DL |
| 9 | congenital Horner syndrome (disease) | KG + DL |
| 10 | congenital entropion | KG + DL |
| 11 | jaw-winking syndrome | KG + DL |
| 12 | lysosomal disease with hypertrophic cardiomyopathy | KG + DL |
| 13 | congenital ectropion | KG + DL |
| 14 | epiblepharon | KG + DL |
| 15 | syndromic neurometabolic disease with X-linked intellectual disability | KG + DL |
| 16 | eyelids malposition disorder | KG + DL |
| 17 | Hurler-Scheie syndrome | KG + DL |
| 18 | Steel syndrome | KG + DL |
| 19 | inborn disorder of lysosomal amino acid transport | KG + DL |
| 20 | phosphoribosylpyrophosphate synthetase superactivity | KG + DL |
| 21 | developmental anomaly of metabolic origin | KG + DL |
| 22 | ocular cystinosis | KG + DL |
| 23 | hypophosphatasia | KG + DL |
| 24 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 25 | proximal myopathy with extrapyramidal signs | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.